How can Balint syndrome be distinguished from posterior cortical atrophy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Distinguishing Balint Syndrome from Posterior Cortical Atrophy

Balint syndrome is a clinical triad of symptoms (optic ataxia, simultanagnosia, and gaze apraxia) that commonly occurs as a manifestation within posterior cortical atrophy (PCA), rather than being a separate diagnostic entity to distinguish from it.

Understanding the Relationship

The key conceptual point is that Balint syndrome represents a specific constellation of neurological signs, while PCA is a neurodegenerative syndrome 1. Approximately half of patients with PCA present with Balint syndrome as part of their clinical picture 2, 3. This is not a differential diagnosis problem—rather, Balint syndrome is one of the core clinical features that helps identify PCA.

Clinical Presentation of PCA

PCA presents with progressive visuospatial and visuoperceptual deficits affecting the dorsal visual stream, typically including 1, 3:

  • Visuospatial construction difficulties (most prominent feature)
  • Gerstmann's syndrome (acalculia, agraphia, finger agnosia, left-right disorientation)
  • Balint syndrome (present in approximately 50% of cases):
    • Optic ataxia (misreaching under visual guidance)
    • Simultanagnosia (inability to perceive multiple objects simultaneously)
    • Oculomotor/gaze apraxia (difficulty directing eye movements voluntarily)
  • Visual object agnosia and prosopagnosia (less common)
  • Alexia and dressing apraxia
  • Relatively preserved memory and language early in disease course (critical distinguishing feature from typical Alzheimer's disease)

Diagnostic Approach

Clinical Screening Tasks

Use figure-ground discrimination as the primary screening measure 2. This task successfully identifies PCA in all patients while being abnormal in only half of typical AD patients and no healthy controls.

Follow with specific assessments for:

  • Balint syndrome components (optic ataxia testing, simultanagnosia evaluation, oculomotor apraxia)
  • Dressing apraxia
  • Ideomotor apraxia
  • Gerstmann's syndrome features

Neuroimaging Findings

Brain MRI without contrast demonstrates bilateral parieto-occipital atrophy (right typically worse than left), which is the hallmark structural finding 4, 5.

FDG-PET/CT shows hypometabolism in the parieto-temporo-occipital cortex and cingulate cortex, with characteristic sparing of the posterior cingulate gyrus that helps distinguish PCA from dementia with Lewy bodies 4, 6.

Tau PET/CT demonstrates greater tau uptake in PCA than in DLB, making it useful when the differential includes Lewy body disease 4.

Key Diagnostic Criteria

Apply the 2017 International Consortium Criteria for PCA with the following core features 3:

  1. Insidious onset and gradual progression
  2. Prominent early visual complaints (not explained by ocular disease)
  3. Significantly greater visuospatial deficits compared to memory and naming (modification allowing for secondary memory/naming difficulty is appropriate based on clinical experience)
  4. Neuroimaging showing predominant occipitoparietal atrophy or hypometabolism

Common Diagnostic Pitfalls

Do not dismiss PCA because memory or language are affected—while these should be relatively spared early, secondary impairment is common and does not exclude the diagnosis 3. The critical distinction is that visuospatial deficits must be significantly more prominent than memory or language problems.

Do not confuse fluctuating cognitive performance or affective symptoms as evidence against neurodegenerative disease—these can occur in PCA and may lead to misdiagnosis as functional/dissociative disorders 7.

Recognize that CSF biomarkers may initially appear inconspicusive despite underlying Alzheimer pathology 7.

Underlying Pathology

PCA is most commonly due to Alzheimer's disease pathology (affecting posterior cortical regions), but can also result from dementia with Lewy bodies, corticobasal degeneration, or prion disease 1. Amyloid PET/CT and tau PET/CT can identify underlying AD pathology when the diagnosis is uncertain 4.

Disease Course

Median survival is approximately 10.3 years, consistent with a slowly progressive neurodegenerative disorder 3. Diagnostic delays of several years are common due to unfamiliarity with the syndrome and atypical presentation 7.

References

Research

Posterior cortical atrophy.

The Lancet. Neurology, 2012

Research

Clinical Screening for Posterior Cortical Atrophy.

Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2022

Research

Benson's Disease or Posterior Cortical Atrophy, Revisited.

Journal of Alzheimer's disease : JAD, 2021

Guideline

acr appropriateness criteria® dementia: 2024 update.

Journal of the American College of Radiology, 2025

Research

The Difficult Diagnosis of Posterior Cortical Atrophy in a 62-Year-Old Woman.

Journal of geriatric psychiatry and neurology, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.